Ying-Jie Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying-Jie Chen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Peiyang Gao
Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
2 shared publications Bo Ye
Department of Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210002, Jiangsu, China
1 shared publicationChang-Hu Yan
Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang, Fujian 362200, P.R. China
1 shared publicationGui-Song Wu
Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China
1 shared publicationHong-Wei Zhang
Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Jinjiang 362200, Fujian province, People's Republic of China
1 shared publicationHongwei Zhang
Department of Critical Care Medicine, Jinjiang Hospital of Traditional Chinese Medicine, Quanzhou, 362201, Fujian, China
1 shared publication
Latest Publications
- Open Access
- 1 September 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 2949-2957
A Systematic Review of Patient Preferences, Expectations, and Values for the Management and Treatment of Graves Disease
Objective: To systematically synthesize evidence on treatment preferences, values, and expectations among patients with Graves’ disease (GD), in order to understand the disease’s impact on quality of life and inform clinical decision-making.. Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for articles about GD, patient preferences, and expectations from database inception to December 2024. Studies included in the review must report raw data on patient-reported outcomes, preferences or experiences relating to GD, and must undergo quality assessment according to the Agency for Healthcare Research and Quality (AHRQ). Results: Twenty-one studies involving patients with GD were included. Although preferences varied, several trends emerged: 1) Most patients reported that GD significantly disrupted their quality of life and social functioning, with 60% experiencing severe discomfort. 2) Antithyroid drugs (ATD) was the most preferred initial treatment (64%), followed by surgery (25%) and radioactive iodine therapy (RAI) (11%), with concerns about radioactivity and surgical complications influencing decisions. 3) Key factors affecting treatment choices included remission rates, recovery time, impact on daily life, and physician recommendations. 4) Graves’ ophthalmopathy (GO) patients faced additional challenges, including social withdrawal and appearance-related distress, with female patients expressing greater concern about disfigurement. Conclusion: This systematic review indicates that GD, particularly GO, significantly impairs patients’ self-confidence, quality of life, and social functioning. Treatment choices are influenced by expected outcomes, personal circumstances, psychological concerns, and economic factors. ATD remains the preferred first-line treatment, though individual preferences vary significantly, emphasizing the importance of personalized approaches and decision aids.
- 1 September 2025
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 19, 2949-2957
Open AccessA Systematic Review of Patient Preferences, Expectations, and Values for the Management and Treatment of Graves Disease
Objective: To systematically synthesize evidence on treatment preferences, values, and expectations among patients with Graves’ disease (GD), in order to understand the disease’s impact on quality of life and inform clinical decision-making.. Methods: PubMed, Embase, Web of Science, and Cochrane Library were searched for articles about GD, patient preferences, and expectations from database inception to December 2024. Studies included in the review must report raw data on patient-reported outcomes, preferences or experiences relating to GD, and must undergo quality assessment according to the Agency for Healthcare Research and Quality (AHRQ). Results: Twenty-one studies involving patients with GD were included. Although preferences varied, several trends emerged: 1) Most patients reported that GD significantly disrupted their quality of life and social functioning, with 60% experiencing severe discomfort. 2) Antithyroid drugs (ATD) was the most preferred initial treatment (64%), followed by surgery (25%) and radioactive iodine therapy (RAI) (11%), with concerns about radioactivity and surgical complications influencing decisions. 3) Key factors affecting treatment choices included remission rates, recovery time, impact on daily life, and physician recommendations. 4) Graves’ ophthalmopathy (GO) patients faced additional challenges, including social withdrawal and appearance-related distress, with female patients expressing greater concern about disfigurement. Conclusion: This systematic review indicates that GD, particularly GO, significantly impairs patients’ self-confidence, quality of life, and social functioning. Treatment choices are influenced by expected outcomes, personal circumstances, psychological concerns, and economic factors. ATD remains the preferred first-line treatment, though individual preferences vary significantly, emphasizing the importance of personalized approaches and decision aids.
- 1 December 2021
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 50, 66-70
Effect of Guo Qing Yi Tang combined with Western medicine cluster therapy on acute pancreatitis
- 1 December 2021
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 50, 66-70
Effect of Guo Qing Yi Tang combined with Western medicine cluster therapy on acute pancreatitis
- Open Access
- 9 November 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (1) , 1
Assessment of acute pancreatitis severity via determination of serum levels of hsa‑miR‑126‑5p and IL‑6
Early assessment of acute pancreatitis (AP) severity is key to its treatment. The present study aimed to explore the role of microRNAs (miRNAs/miRs) combined with inflammatory factors in determining AP severity. For this, serum pro‑inflammatory cytokines [tumor necrosis factor (TNF)‑α, interleukin (IL)‑1, IL‑6, IL‑8 and IL‑10)] and miRNAs [Homo sapiens (hsa)‑miR‑548d‑5p, hsa‑miR‑126‑5p and hsa‑miR‑130b‑5p] were detected in patients with mild AP (MAP), severe AP (SAP) and recurrent AP (RAP). High expression of IL‑10, TNF‑α, hsa‑miR‑126‑5p, hsa‑miR‑548d‑5p and hsa‑miR‑130b‑5p was able to distinguish SAP from MAP and RAP (P<0.05). Multifactorial binary logistic regression analysis indicated that IL‑1/IL‑6 combined with hsa‑miR‑126‑5p/hsa‑miR‑548d‑5p had a significant influence on AP and AP severity (P<0.05). Receiver operating characteristic analysis revealed that IL‑1 combined with hsa‑miR‑126‑5p [area under the curve (AUC), 0.926; sensitivity, 90.0%; specificity, 86.7%, P<0.001] and IL‑6 combined with hsa‑miR‑126‑5p (AUC, 0.952; sensitivity, 93.3%; specificity, 90.0%; P<0.001) were able to better distinguish MAP from SAP than IL‑1/IL‑6 combined with hsa‑miR‑548d‑5p, lipase, and amylase. IL‑1 or IL‑6 combined with hsa‑miR‑548d‑5p (AUC, 0.924; sensitivity, 83.3%; specificity, 93.3%; P<0.001) were able to better distinguish SAP from RAP than IL‑1/IL‑6 combined with hsa‑miR‑126‑5p, lipase, and amylase. IL‑1 combined with hsa‑miR‑126‑5p (AUC, 0.926; sensitivity, 90.0%; specificity, 86.7%; P<0.001) and IL‑6 combined with hsa‑miR‑126‑5p (AUC, 0.952; sensitivity, 93.3%; specificity, 90.0%; P<0.001) were able to better differentiate between MAP and RAP than IL‑1/IL‑6 combined with hsa‑miR‑548d‑5p, lipase, and amylase. These results demonstrated that the combined detection of serum IL‑6 and hsa‑miR‑126‑5p may be useful for the early prediction of AP classification.
- 9 November 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 21 (1) , 1
Open AccessAssessment of acute pancreatitis severity via determination of serum levels of hsa‑miR‑126‑5p and IL‑6
Early assessment of acute pancreatitis (AP) severity is key to its treatment. The present study aimed to explore the role of microRNAs (miRNAs/miRs) combined with inflammatory factors in determining AP severity. For this, serum pro‑inflammatory cytokines [tumor necrosis factor (TNF)‑α, interleukin (IL)‑1, IL‑6, IL‑8 and IL‑10)] and miRNAs [Homo sapiens (hsa)‑miR‑548d‑5p, hsa‑miR‑126‑5p and hsa‑miR‑130b‑5p] were detected in patients with mild AP (MAP), severe AP (SAP) and recurrent AP (RAP). High expression of IL‑10, TNF‑α, hsa‑miR‑126‑5p, hsa‑miR‑548d‑5p and hsa‑miR‑130b‑5p was able to distinguish SAP from MAP and RAP (P<0.05). Multifactorial binary logistic regression analysis indicated that IL‑1/IL‑6 combined with hsa‑miR‑126‑5p/hsa‑miR‑548d‑5p had a significant influence on AP and AP severity (P<0.05). Receiver operating characteristic analysis revealed that IL‑1 combined with hsa‑miR‑126‑5p [area under the curve (AUC), 0.926; sensitivity, 90.0%; specificity, 86.7%, P<0.001] and IL‑6 combined with hsa‑miR‑126‑5p (AUC, 0.952; sensitivity, 93.3%; specificity, 90.0%; P<0.001) were able to better distinguish MAP from SAP than IL‑1/IL‑6 combined with hsa‑miR‑548d‑5p, lipase, and amylase. IL‑1 or IL‑6 combined with hsa‑miR‑548d‑5p (AUC, 0.924; sensitivity, 83.3%; specificity, 93.3%; P<0.001) were able to better distinguish SAP from RAP than IL‑1/IL‑6 combined with hsa‑miR‑126‑5p, lipase, and amylase. IL‑1 combined with hsa‑miR‑126‑5p (AUC, 0.926; sensitivity, 90.0%; specificity, 86.7%; P<0.001) and IL‑6 combined with hsa‑miR‑126‑5p (AUC, 0.952; sensitivity, 93.3%; specificity, 90.0%; P<0.001) were able to better differentiate between MAP and RAP than IL‑1/IL‑6 combined with hsa‑miR‑548d‑5p, lipase, and amylase. These results demonstrated that the combined detection of serum IL‑6 and hsa‑miR‑126‑5p may be useful for the early prediction of AP classification.